Intrust Bank’s Ligand Pharmaceuticals LGND Stock Holding History

Intrust Bank’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,679	Closed	-$289K	–	367
2019 Q1	$289K	Sell	3,679 -343	-9%	-$26K	0.07%	300
2018 Q4	$340K	Sell	4,022 -1,665	-29%	-$177K	0.1%	238
2018 Q3	$974K	Buy	5,687 +30	+0.5%	+$4.52K	0.25%	97
2018 Q2	$731K	Buy	5,657 +263	+5%	+$29.3K	0.2%	130
2018 Q1	$556K	Buy	5,394 +649	+14%	+$64.2K	0.16%	169
2017 Q4	$406K	Buy	4,745 +648	+16%	+$56.2K	0.12%	238
2017 Q3	$348K	Buy	4,097 +639	+18%	+$50.6K	0.11%	253
2017 Q2	$262K	Sell	3,458 -304	-8%	-$21.3K	0.09%	313
2017 Q1	$248K	Sell	3,762 -40	-1%	-$2.63K	0.09%	325
2016 Q4	$241K	Sell	3,802 -138	-4%	-$8.71K	0.09%	316
2016 Q3	$251K	Buy	3,940 +210	+6%	+$15.4K	0.1%	296
2016 Q2	$278K	Buy	+3,730	New	+$277K	0.11%	269

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Intrust Bank's LGND Position: Q2 2019 in Review

Intrust Bank sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 3,679 shares — an estimated $289K sold.

Intrust Bank first reported a position in LGND in Q2 2016 and held it in 12 quarters. The position peaked at $974K in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Intrust Bank reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Intrust Bank sold 3,679 Ligand Pharmaceuticals shares in Q2 2019, an estimated $289K.
Intrust Bank first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 12 quarters.
Intrust Bank's Ligand Pharmaceuticals position peaked at $974K in Q3 2018.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Intrust Bank's 13F filing for Q2 2019, filed 12 Aug 2019.